报价延迟最少15分钟:2026/06/10 10:30 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.0001 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.19/-0.34
|
|
企业价值
7.28M
|
| 资产负债 |
|
每股账面净值
3.03
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.98M
|
|
每股收益
0.94
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours. |
